India based pharmaceutical company, Lupin Limited, announced on Tuesday that it has received approval for its Meloxicam Capsules, 5mg and 10mg, from the United States Food and Drug Administration (US FDA), to market as a generic equivalent of Vivlodex(R) Capsules, 5mg and 1 mg, from Zyla Life Sciences US Inc.
The product will be manufactured at Lupin's Aurangabad facility, India, and is expected to be launched shortly. Meloxicam Capsules, 5mg and 10mg, are indicated for management of osteoarthritis (OA) pain.
Meloxicam Capsules (RLD: Vivlodex(R)) had annual sales of approximately USD14m in the US (IQVIA MAT March 2020).
ScinoPharm Taiwan secures first US FDA approval for complex multiple sclerosis generic
ScinoPharm Taiwan's Glatiramer Acetate Injection approved by US FDA
International Isotopes Inc to change name to Radnostix Inc
Galmed Pharmaceuticals reports topline results for combination of Aramchol, Stivarga and metformin
Ingenus Pharmaceuticals' generic equivalent to Premarin receives US FDA approval
EirGenix signs second global exclusive licensing deal with Sandoz
Padagis invests USD36m to expand manufacturing in Minneapolis
Newbury Pharmaceuticals gains Danish approval for generic ivermectin cream